Charterhouse-backed Cooper bolts on Diepharmex

The vendor of the shares is the Nouvel-Rousselot family. Diepharmex CEO Benjamin Rousselot will act as director of corporate policy on the management board of Alpha HealthGroup, which is the holding company of Cooper and Vemedia.

This is Cooper's second acquisition of 2019 after it acquired assets from Johnson & Johnson earlier this year.

Diepharmex generates a turnover of approximately €15m.

Previous funding
Caravelle took a majority stake in Coopération Pharmaceutique Française, known as Cooper, in 2000. At the time, the company generated revenues of $170m.

In 2015, Charterhouse acquired Cooper in a deal valuing the company at approximately €700m using funds from Charterhouse Capital Partners X.

Charterhouse acquired Vemedia from IK Investment Partners in 2016, planning to merge it with Cooper. The merged company, now called Alpha HealthGroup, was expected to generate revenues of €400m and EBITDA of €100m.

Company
Headquartered in Geneva, Diepharmex manufactures products and drugs for hygiene and ear care. Founded in 1996, it owns the brands Audisray and Micro H, and employs 20 people, according to LinkedIn.

People
Diepharmex – Benjamin Rousselot (CEO).

Advisers
Acquirer – Simmons & Simmons (legal); Lenz & Staehelin (legal).
Company – Python (legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Portfolio management
• DACH
• Healthcare
• healthcare
• France
• Charterhouse Capital Partners
• Switzerland
• Buy-and-build
• Build-up